Bass and Spangenberg file sixth IPR petition, targeting Pharmacyclics
The Coalition for Affordable Drugs has filed another inter partes review petition at the Patent Trial and Appeal Board, in the latest move by Kyle Bass and Erich Spangenberg to target pharmaceutical companies’ patents
The IPR petition challenges claims of US patent 8754090, which is owned by Pharmacyclics. AbbVie announced a deal to buy Pharmacyclics in a $21 billion deal in March. The patent is for the cancer drug Imbruvica and covers methods for...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.